Market Overview

UPDATE: Morgan Stanley Upgrades Becton Dickinson to Equal-Weight on Margin, Organic Growth

Related BDX
Medical Device ETF in Focus on Recent Merger Activity - ETF News And Commentary
Stifel: CareFusion Corporation Deal May Have Far-Flung Effects

Morgan Stanley raised its rating on Becton Dickinson (NYSE: BDX) from Underweight to Equal-weight and removed its price target of $68.

Morgan Stanley commented, "Upgrading BD to Equal-weight from Underweight. Organic growth and leverage are poised for a positive inflection after a two-year investment cycle. We are comfortable with valuation following 12% underperformance in 2012. To move to Overweight, we'd need better visibility on pipeline execution."

Becton Dickinson closed at $79.45 on Wednesday.

Latest Ratings for BDX

DateFirmActionFromTo
Oct 2014Bank of AmericaMaintainsNeutral
Oct 2014Canaccord GenuityMaintainsHold
Oct 2014Argus ResearchMaintainsBuy

View More Analyst Ratings for BDX
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Upgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (BDX)

Around the Web, We're Loving...

Get Benzinga's Newsletters